AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04687098 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous peripheral blood stem cell transplant
Description: To be considered in patients in the intermediate risk group without an available allogeneic donor and negative measurable residual disease, per center decision.
Study NCT04687098 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measurable residual disease
Description: To be performed either with molecular monitoring or, if not applicable, by flow cytometry. Pre-stablished cut-off values are defined for decision-making.
Study NCT03534583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga
Description: Participants in the SKY group will undergo an oline 12-week training course conducted by certified teachers of the Art of Living Foundation
Study NCT03534583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Description: Participants in the online HEP will learn about health promotion, healthy diet, music, and exercise, but will not learn breathing techniques, or meditation. HEP will be delivered by trained staff.
Study NCT00730821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Study NCT00730821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Study NCT02884492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-THK-5351
Description: 18F-THK-5351 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
Study NCT02884492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-THK-5351
Description: 18F-THK-5351 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
Study NCT02884492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture (optional)
Description: Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
Study NCT02884492 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Puncture (optional)
Description: Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
Study NCT01124838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by 40 mg eow starting at Week 1.
Study NCT01124838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.
Study NCT01124838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.
Study NCT05366049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: using a medicine pacifier to give acetaminophen
Description: While giving acetaminophen, the effect on the amount of taking the drug, pain and vital parameters are observed by using the drug pacifier.
Study NCT05366049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: using a medicine pacifier to give acetaminophen
Description: While giving acetaminophen, the effect on the amount of taking the drug, pain and vital parameters are observed by using the drug pacifier.
Study NCT02065570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Study NCT02065570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03600038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental smoking cessation smartphone app
Description: The experimental arm includes an intervention using a novel/experimental smartphone smoking cessation app.
Study NCT03600038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care smoking cessation smartphone app
Description: The control intervention uses a standard of care smartphone smoking cessation app.
Study NCT01013935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CARE+ Spanish computer counseling session
Description: The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 12 months total.
Study NCT01013935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CARE+ Spanish brief computer risk assessment session
Description: The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 12 months total.
Study NCT05276323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medihoney Derma Cream
Description: applied topically, twice a day, on all affected areas in the body for two weeks.
Study NCT05276323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone 1% cream
Description: applied topically, twice a day, on all affected areas in the body for two weeks.
Study NCT00287469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis E vaccine, recombinant (Sar 56 kDa)
Description: 20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)
Study NCT00287469 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBS buffer placebo containing alum
Study NCT00065468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Alfa
Description: Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter.
Study NCT00065468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI-779
Description: 25 mg of CCI-779 given Intra Venously once per week
Study NCT00065468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa and CCI-779
Description: 15 mg of CCI-779 given Intra Venously once per week; 6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week
Study NCT03309124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread
Description: Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
Study NCT03309124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baked potato with skin
Description: Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
Study NCT03073356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of placebo
Description: NaCl
Study NCT04609449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long biliopancreatic limb Roux-en-Y gastric bypass.
Description: Long biliopancreatic limb Roux-en-Y gastric bypass.
Study NCT04609449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Roux-en-Y gastric bypass
Description: Standard Roux-en-Y gastric bypass
Study NCT00003513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients With Metastatic, Recurrent, or Refractory Neuroblastoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT01402986 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Q2W
Description: Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
Study NCT01402986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg, Q2W
Description: Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.
Study NCT01402986 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Q2/4W
Description: Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
Study NCT01402986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg, Q2/4W
Description: Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
Study NCT02227719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTI
Description: CTI is the titanium mesh
Study NCT02227719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen membrane
Study NCT02268682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Guided
Description: The Explore Transplant education program was designed to increase patient informed decision-making and knowledge and is based on the theoretical tenets of the Transtheoretical Model of Behavior Change. The program helps patients think about what might motivate them to pursue transplant, addresses commonly held concerns about transplant and involving a living donor, and shares real-life transplant stories of donors and recipients. The ET materials were written for patients with low health literacy. Already developed for the Explore Transplant program are brochures, videos, and factsheets. ET at Home is an expansion of the ET program. Newly designed postcards and text messages have added to the list of transplant education resources for this program.
Study NCT02268682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educator-Guided
Description: The Transplant Educator supports the Explore Transplant at Home materials by facilitating a conversation about the content of the materials. The role of the Educator is filled by an experienced dialysis healthcare provider who can support a patient as they learn about their treatment options. The program is split into a series of four modules and the Educator conversations are guided by a Transplant Educator Guide and Patient Tracking Tool. This tool is intended to provide direct talking points for the Educator and is also a place where the patients' responses, questions, or concerns can be documented.
Study NCT03009253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: order of treatment
Description: the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.
Study NCT02069093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone based mouthwash
Description: Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.
Study NCT02069093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Commercially available everolimus 10 mg was prescribed to participants by the Investigator according to local regulations.
Study NCT02069093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Commercially available exemestane 25 mg was prescribed to participants by the Investigator according to local regulations.
Study NCT02910934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actellic CS
Description: Indoor residual spray with Actellic CS
Study NCT01897519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion
Study NCT01897519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-719
Description: Arm 1 lower dose, arm 2 intermediate dose, arm 3 high dose
Study NCT00830583 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood test
Description: There is only a blood test at the beginning.
Study NCT04686812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Worksite health promotion program
Description: Physical activity, nutrition, and stress management programs
Study NCT02414789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsies
Description: Skin biopsies of patients with Lyme disease (erythema migrans) infected with Borrelia burgdorferi sensu lato will be analyzed by three diagnostic techniques : molecular technique (PCR), biological technique (culture of the bacteria) and proteomics technique (SRM/ MS-MS)
Study NCT00707642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN-80E
Description: Three injections of the study vaccine \[Low Dose of WN-80E API (5 µg) + Alhydrogel (3.5 mg)\] given one month apart
Study NCT00707642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN-80E
Description: Three injections of the study vaccine \[Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)\] given one month apart
Study NCT00707642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN-80E
Description: Three injections of the study vaccine \[High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)\] given one month apart
Study NCT00707642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN-80E
Description: Three injections of the study vaccine \[High Dose WN-80E API (50 µg)\] given one month apart
Study NCT02748733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted double mini PET
Description: The modified double mini PET mimics the treatment of adapted PD and thus allows its validation
Study NCT02748733 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard double mini PET
Description: The standard double mini PET reflects the routine PD treatment in children and is used for standardized comparison
Study NCT04525326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: mFOLFOX+Cetuximab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis
Study NCT04525326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: mFOLFOX+Bevacizumab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis
Study NCT04525326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX/FOLFIRI ( Standard Chemotherapy)
Description: Standard Chemotherapy
Study NCT02137226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501
Description: BI 695501, every two weeks for 48 weeks (25 injections in total)
Study NCT02137226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Humira®
Description: one injection every 2 weeks for 48 weeks (25 injections in total)
Study NCT00041041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study NCT00041041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02791438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan granules and tablets
Study NCT02791438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching azilsartan granules and tablets
Study NCT01245816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine plus Sulindac
Description: Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
Study NCT01245816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eflornithine plus Placebo
Description: Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
Study NCT01245816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac plus Placebo
Description: Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
Study NCT02432144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX003
Description: solution for intravenous (IV) infusion
Study NCT02062775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of self-fixating mesh for inguinal hernia repair
Description: Parietex ProGrip will be used to repair inguinal hernia
Study NCT02062775 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Use of non-fixating mesh for inguinal hernia repair
Description: Parietex Anatomic mesh will be used to repair inguinal hernias.
Study NCT02062775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable tacks may be used in hernias >2cm
Description: Patients randomized to the Parietex ProGrip study group will be further randomized to either receive absorbable tacks or no tacks if the hernia measures >2cm
Study NCT01124838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT02779270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987518
Description: Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.~Formulation: V27-104
Study NCT02779270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen Lotion (U77-030 Control)
Description: Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.
Study NCT03092934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668
Description: Oral capsules
Study NCT00184093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine weekly x 6 wks with concurrent external radiation
Study NCT02455713 — intervention group
Intervention type: DEVICE
Intervention: PEEP and PIP
Description: Changing ventilator settings and measuring oxygen delivery and cardiac output
Study NCT03765853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy
Description: Usual prevention methods (ergonomic education) and Stretching Postural® postures.
Study NCT03793374 — intervention group
Intervention type: OTHER
Intervention: Subcutaneous apocrine glands shaving
Description: A 0.5-cm long incision was made in the identified elliptical surgical area at each axilla for the access of arthroscopy to remove the apocrine glands. A suction-assisted cartilage shaver (E9005 System, Linvatec Corporation, Largo, Florida, USA) was introduced through the incisions to remove of the subcutaneous apocrine glands radially. After defatting, the incisions were closed primarily with 4-0 polyglactin. We anchored the defatting skin to the axillary fascia by 4-0 nylon sutures instead of the tie-over dressing or tissue glues, and we also made several drainage holes by inserting an 18G needle obliquely into the defatting skin. Therefore, draining tubes were no longer needed. We will remove the stiches at the 8th day after the operation.
Study NCT03712267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Media Enhanced
Description: Research assistants will provide participants' therapists with information from participants' electronic messaging prior to typically scheduled clinical appointments.
Study NCT03712267 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Research assistants will not review or provide participants' therapists with information from participants' electronic media and will compare with the Electronic Media Enhanced cohort to see if there was a difference in therapy outcomes.
Study NCT03167255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-065/NCNP-01
Description: Received during weekly intravenous infusions
Study NCT00758134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab (Herceptin)
Description: Trastuzumab 6 mg/Kg every 3 weeks i.v. (loading dose 8 mg/Kg i.v.)
Study NCT01473706 — intervention group
Intervention type: OTHER
Intervention: Consumer Mini Nutritional Assessment
Description: A 11 question, self administered nutrition screening tool. The consumer and their caregiver will complete the consumer version of the Mini Nutritional Assessment. A healthcare professional will then meet with the consumer and complete a nutrition screening with utilizing a validated nutrition screening tool.
Study NCT03681041 — intervention group
Intervention type: OTHER
Intervention: Standard treatment
Description: Treatment according to guidelines for pancreatic trauma according to the Chinese Trauma Association and the American Association for the Surgery of Trauma
Study NCT01025466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine transdermal patch (Exelon patch), memantine
Description: All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.